Recently, we showed that circulating tumor DNA (ctDNA) measurements may constitute a powerful biomarker for monitoring treatment efficacy during NAC [12], indicating that a combined tumor centric and liquid biopsy approach may be a stronger tool for directing patients to optimal treatment.
![[This page as RDF]](http://data.gesis.org/somesci/static/rdf-icon.gif){kind=icon}